Top Abstract Purchase Related
Home
>
Node
>
Subnode

Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia

Kasper, S.

International Clinical Psychopharmacology 17(Suppl 4): S19-S26

2002

ISSN/ISBN: 0268-1315
PMID: 12685918
Document Number: 542913
This review provides an overview of the evidence related to the role of dopamine deficiency in the pathogenesis of positive and negative schizophrenic symptoms and to the therapeutic use of amisulpride in this indication. It includes concepts of human neurobiology and neuropharmacology and their application to clinical medicine, as well as the presentation of the clinical evidence on the therapeutic efficacy and safety of amisulpride in schizophrenia, highlighting dosage issues.

Document emailed within 1 workday
Secure & encrypted payments

Özdemir, H.İb.; Eker, M.Ça.ğd.ş; Zengin, B.ça.; Yılmaz, D.çe.A.ın.; İşman Haznedaroğlu, D.; Çınar, C.; Kitiş, Öm.; Akay, A.; Gönül, A.S. 2012: Gray matter changes in patients with deficit schizophrenia and non-deficit schizophrenia Turk Psikiyatri Dergisi 23(4): 237-246
French, K.; Eastwood, D. 2003: Response of catatonic schizophrenia to amisulpride: a case report Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 48(8): 570
Pania, L.; Gessab, G.L. 2002: Dopaminergic deficit and mood disorders International Clinical Psychopharmacology 17(Suppl 4): S1
Darcourt, G. 2000: Amisulpride: its role in the therapeutic management of the schizophrenic patient. Introduction Acta Psychiatrica Scandinavica. Supplementum 400: 5-6
Tassin, J.P. 1996: Deficit schizophrenia: from pharmacology to clinical practice L'Encephale 22(Special Issue 2): 9-12
Schooler, N.R.; Keith, S.J.; Severe, J.B.; Matthews, S. 1989: Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 331-335
İnanç, L.; Sevinç, E.ün.; Semiz, Üm.B.şa. 2019: Relationship between Alexithymia, Depression and the Negative Symptoms in Schizophrenia with and without Deficit Syndrome Turk Psikiyatri Dergisi 30(4): 225-235
Herold, R.ób.; Tényi, T.ás.; Simon, M.ár.; Trixler, M.át.ás. 2004: The connection between mentalization deficit and pragmatic language skills and neurocognition in schizophrenia Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet Lapja 6(2): 72-78
León, C.A.; Vigoya, J.; Conde, S.; Campo, G.; Castrillón, E.; León, A. 1994: Comparison of the effect of amisulpride and viloxazine in the treatment of dysthymia Acta Psiquiatrica y Psicologica de America Latina 40(1): 41-49
Mosolov, S.N.; Kabanov, S.O. 2004: Influence of long-term quetiapine (Seroquel) and haloperidol therapy on cognitive deficit in patients with paranoid schizophrenia Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(6): 27-34
Hargreaves, W.A.; Kane, J.M.; Ninan, P.T.; Severe, J.B.; Woerner, M. 1989: Demographic characteristics, treatment history, presenting psychopathology and early course in schizophrenia. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 340-343
Carr, V.J. 1997: The role of the general practitioner in the treatment of schizophrenia: specific issues Medical Journal of Australia 166(3): 143-146
Piyabhan, P.; Wetchateng, T. 2016: Bacopa monnieri (Brahmi) Prevents Cognitive Deficit by Maintaining CA2/3 VGLUT1 Density of Sub-Chronic Phencyclidine Rat Model of Schizophrenia in Normal Level Journal of the Medical Association of Thailand 99 Suppl. 4: S222-S229
Nakayasu, N.; Seki, Y.; Harima, H. 1999: Age of onset, frequency of the development of symptoms, and treatment outcome in the early stage of schizophrenia--in search of guidelines for early diagnosis and treatment of schizophrenia Seishin Shinkeigaku Zasshi 101(11): 898-907
Riederer, P.; Konradi, C.; Youdim, M.B. 1990: The role of MAO in dopaminergic transmission Advances in Neurology 53: 149-153
Delgado, M.; Lopez, F.Z.; Barrios, L. 2006: Déficit de fecundidad en España : factores demográficos que operan sobre una tasa muy inferior al nivel de reemplazo - Fertility deficit in Spain : demographic factors that lower rates to far below the replacement level - Déficit de fertilité en Espagne : facteurs démographiques expliquant des taux très inférieurs au seuil de renouvellement Revista Espanola de Investigaciones Sociologicas (115): 197-222
Vereczkei, A.; Sasvári-Székely, M.ár.; Barta, C. 2009: The role of genetic variants of the dopaminergic system in heroin dependence Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet Lapja 11(2): 95-101
György, L. 1979: Role of dopaminergic and GABA-ergic interactions in seizure susceptibility Archives Internationales de Pharmacodynamie et de Therapie 241(2): 280-286
Napolitano, A.; Cesura, A.M.; Da Prada, M. 1995: The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission Journal of Neural Transmission. Supplementum 45: 35-45
Dadkar, V.N.; Dahanukar, S.A.; Sheth, U.K. 1979: Role of dopaminergic and noradrenergic mechanisms in Metrazole convulsions in mice Indian Journal of Medical Research 70: 492-494